- Roflumilast foam, 0.3%, showed significant scalp itch relief in patients with psoriasis.
- Adolescents and adults with plaque psoriasis participated in the phase 3 trial.
- Patient-reported outcomes improved as early as 24 hours after the first application.
- Higher rates of treatment success were observed in the roflumilast group.
- Most reported adverse events were mild or moderate in severity.
Source: JAMA Dermatology
